These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 28556793)
21. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation. Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323 [TBL] [Abstract][Full Text] [Related]
22. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448 [TBL] [Abstract][Full Text] [Related]
23. Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors. Ren Z; Chen J; Khalil RA Methods Mol Biol; 2017; 1626():79-102. PubMed ID: 28608202 [TBL] [Abstract][Full Text] [Related]
24. [Development of Novel Nuclear Medical Imaging Probes for Quantification of Matrix Metalloproteinases in Diseases]. Kondo N Yakugaku Zasshi; 2020; 140(1):7-13. PubMed ID: 31902888 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299 [TBL] [Abstract][Full Text] [Related]
26. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Zucker S; Cao J; Chen WT Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650 [TBL] [Abstract][Full Text] [Related]
27. Imaging matrix metalloproteinase expression in tumors. Li WP; Anderson CJ Q J Nucl Med; 2003 Sep; 47(3):201-8. PubMed ID: 12897711 [TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinase-Targeted Imaging of Lung Inflammation and Remodeling. Golestani R; Razavian M; Ye Y; Zhang J; Jung JJ; Toczek J; Gona K; Kim HY; Elias JA; Lee CG; Homer RJ; Sadeghi MM J Nucl Med; 2017 Jan; 58(1):138-143. PubMed ID: 27469361 [TBL] [Abstract][Full Text] [Related]
31. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927 [TBL] [Abstract][Full Text] [Related]
32. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Foley LH; Palermo R; Dunten P; Wang P Bioorg Med Chem Lett; 2001 Apr; 11(8):969-72. PubMed ID: 11327602 [TBL] [Abstract][Full Text] [Related]
33. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. Park MJ; Park IC; Hur JH; Kim MS; Lee HC; Woo SH; Lee KH; Rhee CH; Hong SI; Lee SH J Neurosurg; 2002 Jul; 97(1):112-8. PubMed ID: 12134900 [TBL] [Abstract][Full Text] [Related]
34. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography. Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711 [TBL] [Abstract][Full Text] [Related]
35. MMP inhibition by barbiturate homodimers. Wang J; Radomski MW; Medina C; Gilmer JF Bioorg Med Chem Lett; 2013 Jan; 23(2):444-7. PubMed ID: 23246356 [TBL] [Abstract][Full Text] [Related]
36. Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Oltenfreiter R; Staelens L; Labied S; Kersemans V; Frankenne F; Noël A; Van de Wiele C; Slegers G Cancer Biother Radiopharm; 2005 Dec; 20(6):639-47. PubMed ID: 16398616 [TBL] [Abstract][Full Text] [Related]
37. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658 [TBL] [Abstract][Full Text] [Related]
38. Progress in the development of matrix metalloproteinase inhibitors. Tu G; Xu W; Huang H; Li S Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616 [TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment. Yang JS; Lin CW; Su SC; Yang SF Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787 [TBL] [Abstract][Full Text] [Related]
40. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Oltenfreiter R; Staelens L; Lejeune A; Dumont F; Frankenne F; Foidart JM; Slegers G Nucl Med Biol; 2004 May; 31(4):459-68. PubMed ID: 15093816 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]